Amersham

Amersham

Amersham is a world leader in medical diagnostics and in life sciences. They are focused on enabling molecular medicine, working through three main business areas in diagnostic imaging, protein separations and discovery systems.

Headquartered in the UK, they employ over 10,000 people worldwide and had sales of £1.62 billion ($2.54 billion) in 2002. Amersham shares (AHM) are traded on the London, New York and Oslo stock exchanges and we are part of the FTSE index of Britain's 100 largest public companies.

Amersham Health was formed from the merger between Amersham Healthcare (UK) and Nycomed Imaging (Norway) in October 1997. The business is headquartered in Amersham, UK with major regional offices in Oslo, Norway and Princeton, New Jersey, USA.

Amersham is organised in two businesses, Amersham Health (medical diagnostics and therapy products) and Amersham Biosciences (discovery systems and protein separations). The company was formed in 1997 from the mergers of Amersham International (UK), Pharmacia Biotech (Sweden) and Nycomed (Norway). Sir William Castell is Amersham's Chief Executive.Amersham Health provides diagnostic imaging agents which highlight organs, tissues and cells inside the human body, for the early detection, diagnosis and management of disease.

Amersham Biosciences provides enabling technologies for gene and protein research, drug screening and testing, and protein separations systems for the manufacture of biopharmaceuticals.

Amersham's long-term vision is to enable personalised medicine. The aim of personalised medicine is to be able to predict and prevent disease before its symptoms become acute, and treat it with therapies tailored to the individual's genetic profile. Amersham are already working on their three main business areas to help bring about this profound change in healthcare.

In discovery systems, Amersham help scientists understand the role of genes, proteins and cellular processes in disease, and how these affect response to treatment.

Amersham has a long-standing commitment to research and development and a strong track record of innovation in both life sciences and medical diagnostics. They employ more than 1,200 scientists and in 2002 invested £184 million in R&D. Amersham's Portfolio Committee, composed of senior people from the company and external scientists, oversees the research investment across Amersham and identifies the wider market opportunities that spring from their cross-business co-ordination.

Amersham has research, development and manufacturing facilities at some 30 sites in North America, Europe and Asia. Their sales organisation includes offices in more than 50 countries as well as an extensive network of agents and distributors, serving hospitals, clinics, research laboratories, biotechnology firms and pharmaceutical companies across the globe.

Amersham is a world leader in medical diagnostics and in life sciences. Their company is focused on enabling molecular medicine, working through three main business areas in medical diagnostics, protein separations and discovery systems. Headquartered in the UK, we employ over 10,000 people worldwide and had sales of £1.62 billion in 2002. Amersham shares (AHM) are traded on the London, New York and Oslo stock exchanges, and they are part of the FTSE Index of Britain's 100 largest public companies.

Source: www.amersham.co.uk

Login or Register (for FREE) to search and buy a checkSURE Company Credit Report on Amersham